SCHEMBL4398747

SCHEMBL4398747

CC(C)(c1ccc(OCCOC(=O)C2CC3C=CC2C3)cc1)c1ccc(OCCOC(=O)C2CC3C=CC2C3)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.47
HPGD P15428 2/20 0.47
KMT2A Q03164 5/20 0.44
POLB P06746 5/20 0.42
RAB9A P51151 1/20 0.42
TDP1 Q9NUW8 2/20 0.40
APEX1 P27695 1/20 0.40
RECQL P46063 1/20 0.40
BLM P54132 1/20 0.40
ESR2 Q92731 1/20 0.40
HSD17B10 Q99714 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
KDM4E B2RXH2 6/20 0.40
MEN1 O00255 3/20 0.39
HTT P42858 1/20 0.39
ESR1 P03372 1/20 0.39
PSMB1 P20618 1/20 0.38
PSMB5 P28074 1/20 0.38
PSMB2 P49721 1/20 0.38
LMNA P02545 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18901456 0.90 ALDH1A1 (0.41) ALDH1A1HPGDKMT2APOLBRAB9A
SCHEMBL14449133 0.84 ALDH1A1 (0.57) ALDH1A1HPGDKMT2APOLBRAB9A
SCHEMBL4398753 0.84 ALDH1A1 (0.57) ALDH1A1HPGDKMT2APOLBRAB9A
SCHEMBL25567751 0.82 ALDH1A1 (0.38) ALDH1A1HPGDKMT2APOLBRAB9A
SCHEMBL4401219 0.82 ALDH1A1 (0.42) ALDH1A1HPGDKMT2APOLBRAB9A
SCHEMBL9448477 0.82 ALDH1A1 (0.45) ALDH1A1HPGDKMT2APOLBRAB9A
SCHEMBL14213298 0.79 ALDH1A1 (0.53) ALDH1A1HPGDKMT2APOLBRAB9A
SCHEMBL13897067 0.79 ALDH1A1 (0.53) ALDH1A1HPGDKMT2APOLBRAB9A
SCHEMBL10388301 0.79 ALDH1A1 (0.53) ALDH1A1HPGDKMT2APOLBRAB9A
SCHEMBL3291049 0.79 ALDH1A1 (0.47) ALDH1A1HPGDKMT2APOLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018298-A1 OLEFINIC COMPOSITIONS COMPRISING HYDROCARBON RESINS ExxonMobil Product Solutions Company 2024-01-18 US disclosed
US-20230174708-A1 NORBORNENE ESTERS AS COMONOMERS FOR THERMOSET ARTICLES ExxonMobil Product Solutions Company 2023-06-08 US disclosed
US-10729820-B2 Methods and processes for application of drug delivery polymeric coatings ARISTE MEDICAL, LLC (US) 2020-08-04 US disclosed
EP-3134482-B1 METHODS AND PROCESSES FOR APPLICATION OF DRUG DELIVERY POLYMERIC COATINGS ARISTE MEDICAL LLC (US) 2020-06-03 EP disclosed
US-20160101219-A1 METHODS AND PROCESSES FOR APPLICATION OF DRUG DELIVERY POLYMERIC COATINGS ARISTE MEDICAL, INC. 2016-04-14 US disclosed
US-20160101219-A1 METHODS AND PROCESSES FOR APPLICATION OF DRUG DELIVERY POLYMERIC COATINGS ARISTE MEDICAL, INC. 2016-04-14 US disclosed
WO-2015164524-A1 METHODS AND PROCESSES FOR APPLICATION OF DRUG DELIVERY POLYMERIC COATINGS ARISTE MEDICAL, INC. (US) 2015-10-29 WO disclosed
US-8431625-B2 Compositions curable by ring opening metathesis polymerization at low temperatures and their application in the dental field 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-04-30 US disclosed
US-8431625-B2 Compositions curable by ring opening metathesis polymerization at low temperatures and their application in the dental field 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-04-30 US disclosed
US-8178604-B2 Solid materials obtainable by ring-opening metathesis polymerization 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-05-15 US disclosed
US-8178604-B2 Solid materials obtainable by ring-opening metathesis polymerization 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-05-15 US disclosed
US-20100036015-A1 COMPOSITIONS CURABLE BY RING OPENING METATHESIS POLYMERIZATION AT LOW TEMPERATURES AND THEIR APPLICATION IN THE DENTAL FIELD 3M INNOVATIVE PROPERTIES COMPANY 2010-02-11 US disclosed
US-20100036015-A1 COMPOSITIONS CURABLE BY RING OPENING METATHESIS POLYMERIZATION AT LOW TEMPERATURES AND THEIR APPLICATION IN THE DENTAL FIELD 3M INNOVATIVE PROPERTIES COMPANY 2010-02-11 US disclosed
US-20090156735-A1 COMPOSITION, ARTICLE, AND ASSOCIATED METHOD GENERAL ELECTRIC COMPANY (US) 2009-06-18 US disclosed
US-20090156735-A1 COMPOSITION, ARTICLE, AND ASSOCIATED METHOD GENERAL ELECTRIC COMPANY (US) 2009-06-18 US disclosed
US-20090088494-A1 SOLID MATERIALS OBTAINABLE BY RING-OPENING METATHESIS POLYMERIZATION 3M INNOVATIVE PROPERTIES COMPANY 2009-04-02 US disclosed
US-20090088494-A1 SOLID MATERIALS OBTAINABLE BY RING-OPENING METATHESIS POLYMERIZATION 3M INNOVATIVE PROPERTIES COMPANY 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100036015-A1 COMPOSITIONS CURABLE BY RING OPENING METATHESIS POLYMERIZATION AT LOW TEMPERATURES AND THEIR APPLICATION IN THE DENTAL FIELD DNMT3B, HMBS, MMAB ALDH1A1 454/4885HPGD 463/4885KMT2A 1341/4885
US-20090088494-A1 SOLID MATERIALS OBTAINABLE BY RING-OPENING METATHESIS POLYMERIZATION MMAB, DNMT3B, RHEB ALDH1A1 4132/4885HPGD 3718/4885KMT2A 1609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.